These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 27463974)

  • 21. The Role of Cerebrospinal Fluid Biomarkers in the Evolution of Diagnostic Criteria in Alzheimer's Disease: Shortcomings in Prodromal Diagnosis.
    Szalárdy L; Zádori D; Klivényi P; Vécsei L
    J Alzheimers Dis; 2016 May; 53(2):373-92. PubMed ID: 27163812
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease.
    Gui Y; Liu H; Zhang L; Lv W; Hu X
    Oncotarget; 2015 Nov; 6(35):37043-53. PubMed ID: 26497684
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer's and Parkinson's disease.
    Sjödin S; Brinkmalm G; Öhrfelt A; Parnetti L; Paciotti S; Hansson O; Hardy J; Blennow K; Zetterberg H; Brinkmalm A
    Alzheimers Res Ther; 2019 Sep; 11(1):82. PubMed ID: 31521194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cerebrospinal fluid biomarkers for Alzheimer's disease.
    Blennow K; Zetterberg H
    J Alzheimers Dis; 2009; 18(2):413-7. PubMed ID: 19661632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative.
    Molinuevo JL; Blennow K; Dubois B; Engelborghs S; Lewczuk P; Perret-Liaudet A; Teunissen CE; Parnetti L
    Alzheimers Dement; 2014 Nov; 10(6):808-17. PubMed ID: 25150736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases.
    Yin GN; Lee HW; Cho JY; Suk K
    Brain Res; 2009 Apr; 1265():158-70. PubMed ID: 19368810
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders.
    Abdi F; Quinn JF; Jankovic J; McIntosh M; Leverenz JB; Peskind E; Nixon R; Nutt J; Chung K; Zabetian C; Samii A; Lin M; Hattan S; Pan C; Wang Y; Jin J; Zhu D; Li GJ; Liu Y; Waichunas D; Montine TJ; Zhang J
    J Alzheimers Dis; 2006 Aug; 9(3):293-348. PubMed ID: 16914840
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proteomic analysis of cerebrospinal fluid in Alzheimer's disease: wanted dead or alive.
    Oláh Z; Kálmán J; Tóth ME; Zvara Á; Sántha M; Ivitz E; Janka Z; Pákáski M
    J Alzheimers Dis; 2015; 44(4):1303-12. PubMed ID: 25428253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
    Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O
    Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease.
    Antonell A; Mansilla A; Rami L; Lladó A; Iranzo A; Olives J; Balasa M; Sánchez-Valle R; Molinuevo JL
    J Alzheimers Dis; 2014; 42(3):901-8. PubMed ID: 25024322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The association between biomarkers in cerebrospinal fluid and structural changes in the brain in patients with Alzheimer's disease.
    Li X; Li TQ; Andreasen N; Wiberg MK; Westman E; Wahlund LO
    J Intern Med; 2014 Apr; 275(4):418-27. PubMed ID: 24237038
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of cerebrospinal fluid biomarkers to measure change in neurodegeneration in Alzheimer's disease clinical trials.
    Olsson B; Schott JM; Blennow K; Zetterberg H
    Expert Rev Neurother; 2017 Aug; 17(8):767-775. PubMed ID: 28604243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability.
    Fourier A; Portelius E; Zetterberg H; Blennow K; Quadrio I; Perret-Liaudet A
    Clin Chim Acta; 2015 Sep; 449():9-15. PubMed ID: 26141614
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Linking CSF and cognition in Alzheimer's disease: Reanalysis of clinical data.
    Guhra M; Thomas C; Boedeker S; Kreisel S; Driessen M; Beblo T; Ohrmann P; Toepper M
    Exp Gerontol; 2016 Jan; 73():107-13. PubMed ID: 26585048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease.
    Bäckström DC; Eriksson Domellöf M; Linder J; Olsson B; Öhrfelt A; Trupp M; Zetterberg H; Blennow K; Forsgren L
    JAMA Neurol; 2015 Oct; 72(10):1175-82. PubMed ID: 26258692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current state of Alzheimer's fluid biomarkers.
    Molinuevo JL; Ayton S; Batrla R; Bednar MM; Bittner T; Cummings J; Fagan AM; Hampel H; Mielke MM; Mikulskis A; O'Bryant S; Scheltens P; Sevigny J; Shaw LM; Soares HD; Tong G; Trojanowski JQ; Zetterberg H; Blennow K
    Acta Neuropathol; 2018 Dec; 136(6):821-853. PubMed ID: 30488277
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Harnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and Challenges.
    Kim D; Kim YS; Shin DW; Park CS; Kang JH
    J Clin Neurol; 2016 Oct; 12(4):381-392. PubMed ID: 27819412
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
    Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
    J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of CSF biomarkers in the diagnosis of prodromal Alzheimer's disease.
    Parnetti L; Chiasserini D
    Biomark Med; 2011 Aug; 5(4):479-84. PubMed ID: 21861669
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increase of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer's disease and Parkinson's disease.
    Isobe C; Murata T; Sato C; Terayama Y
    Life Sci; 2005 Aug; 77(15):1836-43. PubMed ID: 15935398
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.